{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:48:50Z","timestamp":1782031730398,"version":"3.54.5"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ijrobp.2025.11.005","type":"journal-article","created":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T15:18:58Z","timestamp":1763911138000},"page":"154-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Stereotactic Body Radiation Therapy for Renal Tumors: A Prospective Phase 2 Clinical Trial"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0555-8754","authenticated-orcid":false,"given":"Rachel M.","family":"Glicksman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"McPartlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna T.","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Tsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruz","family":"Mesci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Gutierrez Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Catton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bayley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padraig","family":"Warde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satheesh","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Finelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth T.","family":"Pace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijat","family":"Kitchlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle","family":"Helou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.11.005_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0002","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s11864-023-01161-5","article-title":"Treatment landscape of renal cell carcinoma","volume":"24","author":"Chen","year":"2023","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0003","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European Association of Urology guidelines on renal cell carcinoma: The 2022 update","volume":"82","author":"Ljungberg","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0004","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2214\/ajr.183.1.1830201","article-title":"Percutaneous CT-guided radiofrequency ablation of renal neoplasms: Factors influencing success","volume":"183","author":"Zagoria","year":"2004","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0005","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.31156","article-title":"Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK)","volume":"124","author":"Siva","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0006","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.ijrobp.2020.06.014","article-title":"Stereotactic ablative radiotherapy for \u2265T1b primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK)","volume":"108","author":"Siva","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0007","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S1470-2045(22)00656-8","article-title":"5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: An individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)","volume":"23","author":"Siva","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0008","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1470-2045(24)00020-2","article-title":"Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): A non-randomised phase 2 trial","volume":"25","author":"Siva","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0009","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.radonc.2015.08.030","article-title":"Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma","volume":"117","author":"Ponsky","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0010","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eururo.2023.02.016","article-title":"Phase 2 trial of stereotactic ablative radiotherapy for patients with primary renal cancer","volume":"84","author":"Hannan","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0011","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clon.2022.06.007","article-title":"Stereotactic body radiotherapy for renal cell carcinoma: Oncological and renal function outcomes","volume":"35","author":"Glicksman","year":"2023","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0012","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.clon.2021.03.002","article-title":"Patient-reported quality of life following stereotactic body radiation therapy for primary kidney cancer - Results from a prospective cohort study","volume":"33","author":"Swaminath","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0013","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.ijrobp.2024.07.126","article-title":"Renal function after definitive local therapy for primary renal cell carcinoma: A meta-analysis","volume":"120","author":"Rajoulh","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0014","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.euf.2019.06.002","article-title":"The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: A systematic review and meta-analysis","volume":"5","author":"Correa","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0015","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bju.13811","article-title":"Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: A prospective clinical trial","volume":"120","author":"Siva","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0016","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.radonc.2020.10.031","article-title":"Final results of a dose escalation protocol of stereotactic body radiotherapy for poor surgical candidates with localized renal cell carcinoma","volume":"155","author":"Grubb","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0017","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.prro.2022.06.012","article-title":"Safety and efficacy of stereotactic ablative radiation therapy for renal cell cancer: 24-month results of the RSR1 phase 1 dose escalation study","volume":"13","author":"Lapierre","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0018","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.ijrobp.2023.06.402","article-title":"Final results from a prospective randomized pilot trial of stereotactic body radiation therapy vs. radiofrequency ablation for the Management of Small Renal Masses (RADSTER)","volume":"117","author":"Swaminath","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0019","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(24)00731-9","article-title":"Comparative efficacy and safety of ablative therapies in the management of primary localised renal cell carcinoma: A systematic review and meta-analysis","volume":"26","author":"Huang","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0020","unstructured":"Ljungberg B, Bex A, Albiges L, et al. EAU guidelines on renal cell carcinoma. Accessed December 7, 2024. https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-Guidelines-on-Renal-Cell-Carcinoma-2024.pdf"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0021","unstructured":"NCCN Clincial Practice Guidelines in Oncology (NCCN Guidelines): Kidney cancer. Accessed December 7, 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0022","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.juro.2014.08.044","article-title":"Single fraction radiosurgery for the treatment of renal tumors","volume":"193","author":"Staehler","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0023","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.radonc.2016.01.027","article-title":"Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: Establishing a dose-response relationship","volume":"118","author":"Siva","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0024","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical Practice Guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0025","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: A scientific workshop sponsored by the National Kidney Foundation in Collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0026","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jval.2013.04.015","article-title":"Development and initial validation of the NCCN\/FACT symptom index for advanced kidney cancer","volume":"16","author":"Rothrock","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0027","unstructured":"National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v 5.0. Accessed Jan 4, 2025. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0028","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0029","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/1948550617697177","article-title":"Equivalence Tests: A practical primer for t tests, correlations, and meta-analyses","volume":"8","author":"Lakens","year":"2017","journal-title":"Soc Psychol Personal Sci"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0030","article-title":"Exploring equivalence testing with the updated TOSTER R package","author":"Caldwell","year":"2022","journal-title":"PsyArXiv"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0031","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1200\/JCO.2008.19.6329","article-title":"Multi-institutional phase I\/II trial of stereotactic body radiation therapy for liver metastases","volume":"27","author":"Rusthoven","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0032","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0360-3016(02)03807-5","article-title":"Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer","volume":"55","author":"Tsujino","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0033","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ijrobp.2024.04.066","article-title":"Dose-effect relationship of kidney function after SABR for primary renal cell carcinoma: TROG 15.03 FASTRACK II","volume":"120","author":"Gaudreault","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0034","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ijrobp.2024.05.008","article-title":"FASTRACKing our understanding of renal function after kidney stereotactic ablative body radiation therapy","volume":"120","author":"Glicksman","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0035","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20160113","article-title":"Pulmonary imaging after stereotactic radiotherapy-does RECIST still apply?","volume":"89","author":"Mattonen","year":"2016","journal-title":"Br J Radiol"},{"issue":"suppl 2","key":"10.1016\/j.ijrobp.2025.11.005_bib0036","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.21037\/cco.2017.06.06","article-title":"Challenges in imaging assessment following liver stereotactic body radiotherapy: Pitfalls to avoid in clinical practice","volume":"6","author":"Yip","year":"2017","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0037","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.3171\/2022.8.FOCUS22438","article-title":"Editorial. Assessing treatment response following stereotactic body radiotherapy for spinal metastases","volume":"53","author":"Roth","year":"2022","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0038","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2215\/CJN.0000000000000508","article-title":"Assessment of GFR in patients with cancer: A statement from the American society of onco-nephrology","volume":"19","author":"Kitchlu","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0039","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0270-9295(03)00093-7","article-title":"Radiation nephropathy","volume":"23","author":"Cohen","year":"2003","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.ijrobp.2025.11.005_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110216","article-title":"Dose-response of localized renal cell carcinoma after stereotactic body radiation therapy: A meta-analysis","volume":"194","author":"Huang","year":"2024","journal-title":"Radiother Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625064806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625064806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:33:32Z","timestamp":1782030812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625064806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0360301625064806"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.11.005","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic Body Radiation Therapy for Renal Tumors: A Prospective Phase 2 Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}